Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.265
+0.075 (2.35%)
Apr 29, 2025, 1:10 PM EDT - Market open
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
687.20M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
SVRA News
- 8 days ago - Savara: Make-It-Or-Break-It Molbreevi BLA Filing - Seeking Alpha
- 17 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 21 days ago - Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - Business Wire
- 4 weeks ago - Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Business Wire
- 4 weeks ago - Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 6 weeks ago - Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 - Business Wire
- 7 weeks ago - Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire